Zhang, Lingzhi (2022) Identification of Proteolysis Targeting Chimeras for TPM3-TrkA oncoprotein. [Tesi di dottorato]

[thumbnail of zhang_lingzhi_34_COMPLETO.pdf] Text
zhang_lingzhi_34_COMPLETO.pdf
Visibile a [TBR] Repository staff only

Download (3MB) | Request a copy
[thumbnail of zhang_lingzhi_34_PARZIALE.pdf]
Preview
Text
zhang_lingzhi_34_PARZIALE.pdf

Download (4MB) | Preview
Item Type: Tesi di dottorato
Resource language: English
Title: Identification of Proteolysis Targeting Chimeras for TPM3-TrkA oncoprotein
Creators:
Creators
Email
Zhang, Lingzhi
lingzhi.zhang@unina.it
Date: 9 March 2022
Number of Pages: 70
Institution: Università degli Studi di Napoli Federico II
Department: Medicina Molecolare e Biotecnologie Mediche
Dottorato: Medicina molecolare e biotecnologie mediche
Ciclo di dottorato: 34
Coordinatore del Corso di dottorato:
nome
email
Santoro, Massimo
massimo.santoro@unina.it
Tutor:
nome
email
Santoro, Massimo
UNSPECIFIED
Date: 9 March 2022
Number of Pages: 70
Keywords: PROTAC; TRK oncogenes; pomalidomide
Settori scientifico-disciplinari del MIUR: Area 06 - Scienze mediche > MED/04 - Patologia generale
Date Deposited: 17 Mar 2022 15:04
Last Modified: 28 Feb 2024 14:05
URI: http://www.fedoa.unina.it/id/eprint/14528

Collection description

Tropomyosin receptor kinase A (TrkA) is a transmembrane tyrosine kinase receptor encoded by the neurotrophic tyrosine kinase receptor 1 (NTRK1) gene. NTRK1 fusions have been identified in several cancers, including colorectal, lung, and thyroid carcinomas. The aim of this study was to explore a new strategy to target TrkA fusion proteins, based on Proteolysis Targeting Chimeras (PROTACs). Our study indicated that PROTAC-mediated degradation is a novel and efficient tool to intercept Trk kinase oncogenic signaling as an innovative strategy to treat cancer.

Downloads

Downloads per month over past year

Actions (login required)

View Item View Item